Drug Profile


Alternative Names: SNX-1012

Latest Information Update: 20 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mucosal Therapeutics LLC
  • Developer Coserics
  • Class Antibacterials; Tetracyclines
  • Mechanism of Action Interleukin 6 inhibitors; NF-kappa B inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Stomatitis

Most Recent Events

  • 01 Aug 2007 SNX 1012 is still in phase II trials for Stomatitis in USA
  • 11 Nov 2005 Phase-II clinical trials in Stomatitis in USA (PO)
  • 22 Jun 2005 Phase I trials have been completed in Stomatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top